CoChat

Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor‐κB

Open access
Chung, W. Joon, Sontheimer, Harald · 2009 · Journal of Neurochemistry
Cited by 81

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Nuclear factor‐κB (NF‐κB) is a pleiotropic transcription factor that generally enhances cellular resistance to apoptotic cell death. It has been shown to be constitutively active in some cancers and is being pursued as potential anticancer target. Sulfasalazine which is used clinically to treat Crohn’s disease has emerged as a potential inhibitor of NF‐κB and has shown promising results in two pre‐clinical studies to target primary brain tumors, gliomas. Once digested, sulfasalazine is cleaved into sulfapyridine and 5‐aminosalicylic acid (5‐ASA; mesalamine) by colonic bacteria, and the latter, too, is reported to suppress NF‐κB activity. We now show that glioma cells obtained from patient biopsies or glioma cell lines do not show significant constitutive NF‐κB activation, unless exposed to inflammatory cytokines. This does not change when gliomas are implanted into the cerebrum of severe combined immundeficient mice. Nevertheless, sulfasalazine but not its cleaved form 5‐ASA caused a dose‐dependent inhibition of glioma growth. This effect was entirely attributable to the inhibition of cystine uptake via the system x c− cystine–glutamate transporter. It could be mimicked by S‐4‐carboxy‐phenylglycine (S‐4‐CPG) a more specific system x c− inhibitor, and lentiviral expression of a constitutively active form of IκB kinase b was unable to overcome the growth retarding effects of sulfasalazine or S‐4‐CPG. Both drugs inhibited cystine uptake causing a chronic depletion of intracellular GSH and consequently compromised cellular redox defense which stymied tumor growth. This data suggests that system x c− is a promising therapeutic target in gliomas and possibly other cancers and that it can be pharmacologically inhibited by Sulfasalazine, an FDA‐approved drug.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1471-4159.2009.06129.x

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 81

Metadata

Authors
Chung, W. J., & Sontheimer, H.
Venue
Journal of Neurochemistry
Publisher
Wiley
Published
2009-06-15
Volume
110
Issue
1
Pages
182-193
ISSN
  • 0022-3042 (ISSN-L)
  • 1471-4159
OpenAlex
W2070619895
Cited by
81
References
7
FWCI
2.46
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor‐κB. https://app.cochat.ai/papers/10.1111/j.1471-4159.2009.06129.x
The paper
Chung, W. J., & Sontheimer, H. (2009). Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor‐κB. Journal of Neurochemistry. https://doi.org/10.1111/j.1471-4159.2009.06129.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.